High-titer acquired factor V inhibitor responsive to corticosteroids and cyclophosphamide in a patient with two malignant tumors.
We report a 79-year-old man with two simultaneous malignant tumors (buccal epidermoid carcinoma and prostatic adenocarcinoma) who developed a severe bleeding complication at the site of the buccal tumor as well as a massive cerebral hematoma after a skull trauma. Laboratory findings showed the presence of a high-titer specific factor V inhibitor. The patient failed to respond to intravenous immunoglobulins, but both clinical and laboratory improvement was obtained after treatment with corticosteroids and cyclophosphamide.
Bayani
Nazanine
N
Hematology Laboratory, Créteil Intercommunal Hospital Center, France. nazanine.bayani@chicreteil.fr
Rugina
Michel
M
Haddad-Vergnes
Laurence
L
Lelong
Françoise
F
D000230:Adenocarcinoma / Q000276:immunology*; D000368:Aged; D001323:Autoantibodies / Q000096:biosynthesis* / Q000276:immunology; D001327:Autoimmune Diseases / Q000209:etiology* / Q000276:immunology; D002294:Carcinoma, Squamous Cell / Q000276:immunology*; D002543:Cerebral Hemorrhage / Q000209:etiology; D006259:Craniocerebral Trauma / Q000150:complications; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005165:Factor V / Q000276:immunology*; D006470:Hemorrhage / Q000209:etiology* / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D009062:Mouth Neoplasms / Q000276:immunology*; D009378:Neoplasms, Multiple Primary / Q000276:immunology*; D011241:Prednisone / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000276:immunology*
D001323:Autoantibodies; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D005165:Factor V; D011241:Prednisone